The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia

E-ISSN： 1873-4286|23|10|1495-1499

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.23, Iss.10, 2017-05, pp. : 1495-1499

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Proprotein Convertase Subtilisin/kexin type 9 Inhibition in Cardiovascular Prevention

Current Pharmaceutical Design, Vol. 24, Iss. 4, 2018-04 ,pp. : 442-450

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Hyperlipidemia: Focus on Therapeutic Implications

By Farnier Michel

American Journal of Cardiovascular Drugs, Vol. 11, Iss. 3, 2011-06 ,pp. : 145-152

Adis International

Access to resources Recommend Favorite

Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia

By Lee Paul Hegele Robert A

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 11, 2013-11 ,pp. : 1411-1423

Informa Healthcare

Access to resources Recommend Favorite

Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies

Current Pharmaceutical Design, Vol. 19, Iss. 17, 2013-05 ,pp. : 3161-3172

Bentham Science Publishers

Access to resources Recommend Favorite

Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents

By Abifadel Marianne Pakradouni Jihane Collin Matthieu Samson-Bouma Marie-Elisabeth Varret Mathilde Rabès Jean-Pierre Boileau Catherine

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 11, 2010-11 ,pp. : 1547-1571

Informa Healthcare

Access to resources Recommend Favorite